Pfizer said Tuesday it expects its sales and earnings for 2025 to bracket the forecasts of sell-side analysts and investors, leaving room for debate on a company whose stock has struggled since its highs during the Covid pandemic.
The drug giant, which makes breast cancer drug Ibrance, pneumococcal vaccine Prevnar, and the heart drug Vyndaqel, said it expects sales next year to fall between $61 billion and $64 billion, and that diluted earnings per share, a key measure watched by investors, would range between $2.80 and $3.00 per share.
Financial analysts polled by Visible Alpha had expected earnings per share of $2.89 and sales of $63.2 billion. In a note to clients Monday, Akash Tewari, an analyst at Jefferies, wrote that the consensus among fund managers (the “buy side”) was actually lower, with a forecasted dilute earnings per share of $2.50 to $2.70.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
